Clinical Trial Update: Psilocybin Versus Ketamine in Treatment-Resistant Depression [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing psilocybin to ketamine in treatment-resistant depression (NCT05383313).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Treatment-resistant Depression

Drugs mentioned

• Ketamine (ketamine)
• Psilocybin (psilocybin)

Snippet

Sponsor: National Institute of Mental Health, Czech Republic | Conditions: Treatment Resistant Depression | Phase 2 | Status: UNKNOWN